Results 121 to 130 of about 88,199 (267)

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of a Phase 3, Randomized, Placebo‐Controlled Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective To evaluate the efficacy and safety of guselkumab, an interleukin‐23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor (TNF) inhibitor.
Alexis Ogdie   +12 more
wiley   +1 more source

Unveiling Endotypes in Systemic Lupus Erythematosus Through Multiomic Analysis: Insights Into Cardiovascular and Renal Complications

open access: yesArthritis &Rheumatology, EarlyView.
Objective Systemic lupus erythematosus (SLE) shows clinical and molecular heterogeneity, and cardiovascular (CV) complications and lupus nephritis (LN) remain leading causes of morbidity and mortality. This study investigated whether omic profiling can reveal molecular endotypes linked to these outcomes.
Tomás Cerdó   +84 more
wiley   +1 more source

Validation of International Classification of Diseases Code–Based Case Definitions of Immune Checkpoint Inhibitor–Associated Inflammatory Arthritis From Administrative Health Data

open access: yesArthritis &Rheumatology, EarlyView.
Objective Immune checkpoint inhibitors (ICIs) for cancer can lead to immune‐related adverse events, including ICI‐associated inflammatory arthritis (ICI‐IA). There are no validated International Classification of Diseases (ICD) code–based case definitions for ICI‐IA.
Manar Elsayed   +11 more
wiley   +1 more source

Clinical Images: Subcutaneous panniculitis‐like T cell lymphoma

open access: yes
Arthritis &Rheumatology, EarlyView.
S Chambers, CN Myrdal, VP Werth
wiley   +1 more source

Machine Learning to Predict Remission Between 6 and 24 Months in Rheumatoid Arthritis: Insights From JAK, an International Registry Collaboration

open access: yesArthritis &Rheumatology, EarlyView.
Objective To develop, externally validate, and simplify a machine learning model to predict remission between 6 and 24 months in patients with rheumatoid arthritis (RA) initiating tumor necrosis factor inhibitors, JAK inhibitors, interleukin‐6 inhibitors, abatacept, or rituximab using data from 11 international registries in the JAK‐pot collaboration ...
Zubeyir Salis   +22 more
wiley   +1 more source

Drug-induced dermatomyositis after lacosamide: A case report. [PDF]

open access: yes, 2018
Here we describe a caseof a woman who had DM after treatment withlacosamide.
Gaffney, Rebecca G.   +2 more
core   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun   +4 more
wiley   +1 more source

Voclosporin‐induced gingival enlargement: A case report

open access: yesClinical Advances in Periodontics, EarlyView.
Abstract Background Drug‐influenced gingival enlargement (DIGE) is a recognized adverse effect of certain medications, particularly immunosuppressants like cyclosporin and tacrolimus. However, there have been no documented cases of DIGE associated with voclosporin, a newer calcineurin inhibitor used primarily to treat lupus nephritis.
Francesca Racca   +2 more
wiley   +1 more source

Novel Organelle‐Based Intracellular Immunity With Mechanistic and Therapeutic Implications

open access: yesBarrier Immunity, EarlyView.
A conceptual framework illustrating how PAMPs/DAMPs initiate barrier, innate, adaptive, and intracellular immune responses, with organelle‐based intracellular immunity serving as a central integrator linking metabolism, inflammatory signaling, and therapeutic interventions to restore immune homeostasis.
Keman Xu   +9 more
wiley   +1 more source

Transmission Raman Spectroscopy (TRS) for Accurate Authentication of API in Coated Hydroxychloroquine (HCQ) Tablets

open access: yesJournal of Raman Spectroscopy, EarlyView.
We report the development and use of a transmission Raman spectroscopy (TRS) system for a more accurate but nonintrusive way of authentication of API in coated HCQ tablets which otherwise is not possible using the backscattered (BS) configuration of Raman spectroscopy. The coating interference is found to be almost zero in case of the TRS and a greater
Vijay Kumar   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy